MX367319B - Nuevos derivados de fosfinanos y azafosfinanos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen. - Google Patents

Nuevos derivados de fosfinanos y azafosfinanos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.

Info

Publication number
MX367319B
MX367319B MX2018008639A MX2018008639A MX367319B MX 367319 B MX367319 B MX 367319B MX 2018008639 A MX2018008639 A MX 2018008639A MX 2018008639 A MX2018008639 A MX 2018008639A MX 367319 B MX367319 B MX 367319B
Authority
MX
Mexico
Prior art keywords
phosphinans
aaphosphinanes
contain
pharmaceutical compositions
preparation procedure
Prior art date
Application number
MX2018008639A
Other languages
English (en)
Other versions
MX2018008639A (es
Inventor
Rupin Alain
Sansilvestri-Morel Patricia
Vallez Marie-Odile
Gloanec Philippe
Mennecier Philippe
Pierre SCHAFFNER Arnaud-
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55752640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX367319(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of MX2018008639A publication Critical patent/MX2018008639A/es
Publication of MX367319B publication Critical patent/MX367319B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6568Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C07F9/65846Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a six-membered ring which may be condensed with another ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Compuestos de fórmula (I) (ver Fórmula) en la que: Ak1 representa una cadena alquilo, X representa -(CH2)m-,-CH (R)-,-N(R)-,-CH2-N(R)-,-N (R)-CH2-o-CH2-N(R)-CH2-,m y R son tales como se han definido en la descripción, R1 y R2 representan cada uno H cuando X representa -(CH2)m-,-CH (R)-,-N (R)-,-CH2-N(R)-o-N (R)-CH2-, o bien forman juntos una unión cuando X representa -CH2-N (R)-CH2-,R3 representa NH2, Cy-NH2, Cy-Ak3-NH2 o piperidin-4-ilo, Cy y Ak3 son tales como se han definido en la descripción, R4 y R5, idénticos o diferentes, representan cada uno H o F, sus isómeros ópticos, así como sus sales de adición a un ácido farmacéuticamente aceptable.Medicamentos.
MX2018008639A 2016-01-14 2017-01-13 Nuevos derivados de fosfinanos y azafosfinanos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen. MX367319B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1670004A FR3046793B1 (fr) 2016-01-14 2016-01-14 Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/FR2017/050075 WO2017121969A1 (fr) 2016-01-14 2017-01-13 Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
MX2018008639A MX2018008639A (es) 2018-11-19
MX367319B true MX367319B (es) 2019-08-15

Family

ID=55752640

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008639A MX367319B (es) 2016-01-14 2017-01-13 Nuevos derivados de fosfinanos y azafosfinanos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.

Country Status (47)

Country Link
US (2) US10138260B2 (es)
EP (1) EP3271368B1 (es)
JP (1) JP2019504070A (es)
KR (1) KR20180101522A (es)
CN (1) CN108495857A (es)
AR (1) AR107433A1 (es)
AU (1) AU2017207003B2 (es)
BR (1) BR112018014020A2 (es)
CA (1) CA3011184C (es)
CL (1) CL2018001862A1 (es)
CO (1) CO2018007271A2 (es)
CU (1) CU20180072A7 (es)
CY (1) CY1121154T1 (es)
DK (1) DK3271368T3 (es)
DO (1) DOP2018000165A (es)
EA (1) EA035072B1 (es)
EC (1) ECSP18051972A (es)
ES (1) ES2709376T3 (es)
FR (1) FR3046793B1 (es)
GE (2) GEAP201914853A (es)
HK (1) HK1244283B (es)
HR (1) HRP20190193T1 (es)
HU (1) HUE042924T2 (es)
IL (1) IL260425B (es)
JO (1) JO3660B1 (es)
LT (1) LT3271368T (es)
MA (1) MA41798B1 (es)
MD (1) MD3271368T2 (es)
ME (1) ME03305B (es)
MX (1) MX367319B (es)
NI (1) NI201800073A (es)
PE (1) PE20181503A1 (es)
PH (1) PH12018501373A1 (es)
PL (1) PL3271368T3 (es)
PT (1) PT3271368T (es)
RS (1) RS58338B1 (es)
RU (1) RU2729641C2 (es)
SG (1) SG11201805757WA (es)
SI (1) SI3271368T1 (es)
SV (1) SV2018005721A (es)
TN (1) TN2018000226A1 (es)
TR (1) TR201820430T4 (es)
TW (1) TWI625334B (es)
UA (1) UA121275C2 (es)
UY (1) UY37072A (es)
WO (1) WO2017121969A1 (es)
ZA (1) ZA201804391B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3046793B1 (fr) * 2016-01-14 2018-01-05 Les Laboratoires Servier Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE447557T1 (de) * 2000-08-17 2009-11-15 Pfizer Ltd Substitutuierte imidazole als tafia inhibitoren
SE0103272D0 (sv) * 2001-09-28 2001-09-28 Astrazeneca Ab Chemical compounds
WO2003076416A1 (en) * 2002-03-08 2003-09-18 Warner-Lambert Company Llc Oxo azabicyclic compounds
US7420000B2 (en) * 2003-09-10 2008-09-02 University Of Southern California Amino phosphonate and amino bis-phosphonate derivatives
WO2005058330A1 (en) * 2003-12-17 2005-06-30 Quatrx Pharmaceuticals Co. Phosphorus containing compounds useful for the regulation of ldl and lp(a) levels
JP2008536923A (ja) * 2005-04-18 2008-09-11 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 心筋の再灌流の増強およびpciの容易化のためのtafi阻害剤の使用
JP5478488B2 (ja) * 2007-06-20 2014-04-23 メルク・シャープ・アンド・ドーム・コーポレーション Janusキナーゼの阻害剤
FR2920773B1 (fr) * 2007-09-11 2009-10-23 Servier Lab Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2947266B1 (fr) * 2009-06-26 2011-06-17 Servier Lab Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2011031669A1 (en) * 2009-09-09 2011-03-17 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
BR112014030284B1 (pt) * 2012-07-18 2021-11-30 Sunshine Lake Pharma Co., Ltd Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
FR3046793B1 (fr) * 2016-01-14 2018-01-05 Les Laboratoires Servier Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
US10654878B2 (en) 2020-05-19
PE20181503A1 (es) 2018-09-18
RS58338B1 (sr) 2019-03-29
GEP20207092B (en) 2020-04-10
ECSP18051972A (es) 2018-07-31
PT3271368T (pt) 2018-12-04
AU2017207003A2 (en) 2018-10-04
TW201726697A (zh) 2017-08-01
AU2017207003B2 (en) 2020-10-08
EP3271368A1 (fr) 2018-01-24
EP3271368B1 (fr) 2018-10-31
LT3271368T (lt) 2018-12-10
NI201800073A (es) 2018-09-06
UA121275C2 (uk) 2020-04-27
MA41798A (fr) 2018-01-24
FR3046793B1 (fr) 2018-01-05
CA3011184A1 (fr) 2017-07-20
PH12018501373B1 (en) 2019-02-27
PH12018501373A1 (en) 2019-02-27
ZA201804391B (en) 2020-01-29
AU2017207003A1 (en) 2018-07-26
US20190031693A1 (en) 2019-01-31
CY1121154T1 (el) 2020-05-29
US20180016288A1 (en) 2018-01-18
RU2018129027A (ru) 2020-02-14
TR201820430T4 (tr) 2019-01-21
US10138260B2 (en) 2018-11-27
JP2019504070A (ja) 2019-02-14
CO2018007271A2 (es) 2018-07-19
KR20180101522A (ko) 2018-09-12
ME03305B (me) 2019-10-20
SG11201805757WA (en) 2018-08-30
SV2018005721A (es) 2018-09-06
CN108495857A (zh) 2018-09-04
IL260425B (en) 2020-05-31
HUE042924T2 (hu) 2019-07-29
MX2018008639A (es) 2018-11-19
MD3271368T2 (ro) 2019-03-31
CA3011184C (fr) 2020-09-29
RU2018129027A3 (es) 2020-03-19
DK3271368T3 (da) 2019-02-25
ES2709376T3 (es) 2019-04-16
HRP20190193T1 (hr) 2019-04-05
FR3046793A1 (fr) 2017-07-21
JO3660B1 (ar) 2020-08-27
GEAP201914853A (en) 2019-12-10
EA035072B1 (ru) 2020-04-23
SI3271368T1 (sl) 2019-02-28
PL3271368T3 (pl) 2019-04-30
DOP2018000165A (es) 2018-09-15
CL2018001862A1 (es) 2018-10-05
TWI625334B (zh) 2018-06-01
MA41798B1 (fr) 2018-11-30
BR112018014020A2 (pt) 2018-12-11
HK1244283B (zh) 2019-11-22
TN2018000226A1 (fr) 2019-10-04
EA201891599A1 (ru) 2019-01-31
WO2017121969A1 (fr) 2017-07-20
RU2729641C2 (ru) 2020-08-11
CU20180072A7 (es) 2018-10-04
UY37072A (es) 2017-07-31
AR107433A1 (es) 2018-05-02

Similar Documents

Publication Publication Date Title
NI201800132A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
MX2018003432A (es) Compuestos heterociclicos y usos de los mismos.
MX381707B (es) Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
NI201800076A (es) Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen
CR20160291A (es) Análogos de cortistatina y síntesis y usos de los mismos
ECSP109944A (es) Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparación, su aplicación como medicamentos, composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met
MX2018004008A (es) Inhibidores de isoindolinona de la interaccion mdm2-p53 que tienen actividad antineoplasica.
EA202191114A1 (ru) Производные пиридинилсульфонамида, фармацевтические композиции и их применение
CO6331467A2 (es) Nuevos derivados de imidazo(1,2-a)piridina, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion particularmente como inhibidores de met
MX2018003993A (es) Inhibidores de isoindolinona de la interaccion mdm2-p53 que tienen actividad antineoplasica.
EP4028015A4 (en) Ophthalmic formulations of methotrexate
EP3827842A4 (en) COMPOSITION WITH INFLUENZA VACCINE
MX374383B (es) Derivados de carboxamida como inhibidores de smurf-1
CO2017009989A2 (es) Piridopirimidinonas y utilización de las mismas como moduladores de receptores de nmda
CR20130318A (es) Nuevos compuestos de benzodioxol-piperazina
CO2018012020A2 (es) Derivados de piridinilo, composiciones farmacéuticas y sus usos como inhibidores aoc3
AR109168A1 (es) Sales de derivados de 2,6-dimetilpirimidona y sus usos
UY29468A1 (es) Nuevos derivados de isoindoles, composiciones que los contienen, su preparación y sus utilizaciones farmacéuticas, especialmente como inhibidores de las actividades de la proteína chaperona hsp90.
JOP20170127A1 (ar) صيغة مشتركة مكونة من ثلاث مركبات مضادة للفيروسات
NI201800073A (es) Nuevos derivados de fosfinanos y azafosfinanos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
ECSP12012329A (es) Nueva asociación entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un antagonista de los receptores nmda y las composiciones farmacéuticas que la contienen

Legal Events

Date Code Title Description
FG Grant or registration